Advertisement

Digestive Diseases and Sciences

, Volume 50, Issue 11, pp 2009–2018 | Cite as

Efficacy of Rabeprazole in the Treatment of Symptomatic Gastroesophageal Reflux Disease

  • Peter J. Kahrilas
  • Philip Miner
  • John Johanson
  • Lian Mao
  • Leonard Jokubaitis
  • Sheldon Sloan
Article

Abstract

The purpose of this study was to assess the rapidity of symptom relief and 4-week efficacy of rabeprazole 20 mg in patients with moderately severe nonerosive gastroesophageal reflux disease. Data were analyzed from 2 similarly designed, double-blind, placebo-controlled, multicenter, U.S. trials. After a 2-week placebo run-in period, patients (N = 261) were randomized to 4 weeks of rabeprazole 20 mg once daily or placebo. Patients kept symptom diaries and scored symptom severity. Median time to first 24-hour heartburn-free interval was 3.5 days for the rabeprazole group compared with 19.5 days for the placebo group (P ≤ .0002). Complete heartburn relief at week 4 was 32% with rabeprazole and 3.8% with placebo (P ≤ .001). Rabeprazole also significantly improved other GERD-associated symptoms (e.g., regurgitation, belching, early satiety) by week 4 compared with placebo (P ≤ .05). Rabeprazole provides fast and potent relief from heartburn and other symptoms of nonerosive gastroesophageal reflux disease.

Keywords

gastroesophageal reflux disease symptoms nonerosive gastroesophageal reflux disease proton pump inhibitor rabeprazole 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    A Gallup Organization National Survey: Heartburn across America. Princeton, NJ, Gallup Organization, 1988Google Scholar
  2. 2.
    Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd: Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 112:1448–1456, 1997PubMedGoogle Scholar
  3. 3.
    Lind T, Havelund T, Carlsson R, et al.: Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 32:974–979, 1997PubMedGoogle Scholar
  4. 4.
    Jones T: Can we alter the cytokine balance in the management of infectious diseases? Braz J Infect Dis 1:149–150, 1997PubMedGoogle Scholar
  5. 5.
    Galmiche JP, Barthelemy P, Hamelin B: Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther 11:765–773, 1997CrossRefPubMedGoogle Scholar
  6. 6.
    Smout AJ: Endoscopy-negative acid reflux disease. Aliment Pharmacol Ther 22:81–85, 1997Google Scholar
  7. 7.
    Havelund T, Lind T, Wiklund I, et al.: Quality of life in patients with heartburn but without esophagitis: effects of treatment with omeprazole. Am J Gastroenterol 94:1782–1789, 1999CrossRefPubMedGoogle Scholar
  8. 8.
    Revicki DA, Wood M, Maton PN, Sorensen S: The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med 104:252–258, 1998CrossRefPubMedGoogle Scholar
  9. 9.
    Clouse RE, Richter JE, Heading RC, Janssens J, Wilson JA: Functional esophageal disorders. Gut 45(Suppl 2):II31–II36, 1999PubMedGoogle Scholar
  10. 10.
    Masclee AA, de Best AC, de Graaf R, Cluysenaer OJ, Jansen JB: Ambulatory 24-hour pH-metry in the diagnosis of gastroesophageal reflux disease. Determination of criteria and relation to endoscopy. Scand J Gastroenterol 25:225–230, 1990PubMedGoogle Scholar
  11. 11.
    Mattioli S, Pilotti V, Spangaro M, et al.: Reliability of 24-hour home esophageal pH monitoring in diagnosis of gastroesophageal reflux. Dig Dis Sci 34:71–78, 1989CrossRefPubMedGoogle Scholar
  12. 12.
    Baldi F, Ferrarini F, Longanesi A, Ragazzini M, Barbara L: Acid gastroesophageal reflux and symptom occurrence. Analysis of some factors influencing their association. Dig Dis Sci 34:1890–1893, 1989CrossRefPubMedGoogle Scholar
  13. 13.
    Wiener GJ, Richter JE, Copper JB, Wu WC, Castell DO: The symptom index: a clinically important parameter of ambulatory 24-hour esophageal pH monitoring. Am J Gastroenterol 83:358–361, 1988PubMedGoogle Scholar
  14. 14.
    Breumelhof R, Smout AJ: The symptom sensitivity index: a valuable additional parameter in 24-hour esophageal pH recording. Am J Gastroenterol 86:160–164, 1991PubMedGoogle Scholar
  15. 15.
    Weusten BL, Roelofs JM, Akkermans LM, Van Berge-Henegouwen GP, Smout AJ: The symptom-association probability: an improved method for symptom analysis of 24-hour esophageal pH data. Gastroenterology 107:1741–1745, 1994PubMedGoogle Scholar
  16. 16.
    Williams MP, Sercombe J, Hamilton MI, Pounder RE: A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther 12:1079–1089, 1998CrossRefPubMedGoogle Scholar
  17. 17.
    Cloud ML, Enas N, Humphries TJ, Bassion S: Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group. Dig Dis Sci 43:993–1000, 1998CrossRefPubMedGoogle Scholar
  18. 18.
    Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ: Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group. Aliment Pharmacol Ther 13:49–57, 1999PubMedGoogle Scholar
  19. 19.
    Thjodleifsson B, Beker JA, Dekkers C, Bjaaland T, Finnegan V, Humphries TJ: Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group. Dig Dis Sci 45:845–853, 2000CrossRefPubMedGoogle Scholar
  20. 20.
    Miner P Jr, Orr W, Filippone J, Jokubaitis L, Sloan S: Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenterol 97:1332–1339, 2002CrossRefPubMedGoogle Scholar
  21. 21.
    Johanson J, Miner P, Jokubaitis L, Mao L, Sloan S: Rabeprazole significantly improves heartburn vs placebo in endoscopically negative GERD patients with moderate to severe symptoms [abstract]. Am J Gastroenterol 96(Suppl):S18, 2001CrossRefGoogle Scholar
  22. 22.
    Bate CM, Griffin SM, Keeling PW, et al.: Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis. Aliment Pharmacol Ther 10:547–555, 1996CrossRefPubMedGoogle Scholar
  23. 23.
    Storr M, Meining A, Allescher HD: Pathophysiology and pharmacological treatment of gastroesophageal reflux disease. Dig Dis 18:93–102, 2000CrossRefPubMedGoogle Scholar
  24. 24.
    Soll AH, Fass R: Gastroesophageal reflux: practical management of a common, challenging disorder. Clin Cornerstone 1:1–17, 1999CrossRefGoogle Scholar
  25. 25.
    Lambert R: Review article: current practice and future perspectives in the management of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 11:651–662, 1997CrossRefPubMedGoogle Scholar
  26. 26.
    Freston JW, Malagelada JR, Petersen H, McCloy RF: Critical issues in the management of gastroesophageal reflux disease. Eur J Gastroenterol Hepatol 7:577–586, 1995PubMedGoogle Scholar
  27. 27.
    Sanders SW: Pathogenesis and treatment of acid peptic disorders: comparison of proton pump inhibitors with other antiulcer agents. Clin Ther 18:2–34, 31, 1996Google Scholar
  28. 28.
    Bruley des Varannes S, Galmiche JP: Evaluation of Esophageal Sensitivity, vol. 22. Basel, Karger, 1994Google Scholar
  29. 29.
    Pehlivanov N, Liu J, Mittal R: Sustained esophageal contraction: a motor correlate of heartburn symptom [abstract # G4613]. Gastroenterology 116:1999Google Scholar
  30. 30.
    Trimble KC, Pryde A, Heading RC: Lowered oesophageal sensory thresholds in patients with symptomatic but not excess gastro-oesophageal reflux: evidence for a spectrum of visceral sensitivity in GORD. Gut 37:7–12, 1995PubMedGoogle Scholar
  31. 31.
    Meyer JH, Lembo A, Elashoff JD, Fass R, Mayer EA: Duodenal fat intensifies the perception of heartburn. Gut 49:624–628, 2001CrossRefPubMedGoogle Scholar
  32. 32.
    Carlsson R, Dent J, Watts R, et al: Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 10:119–124, 1998PubMedGoogle Scholar
  33. 33.
    Katz PO, Castell DO, Levine D: Esomeprazole resolves chronic heartburn in patients without erosive oesophagitis. Aliment Pharmacol Ther 18:875–882, 2003CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, Inc. 2005

Authors and Affiliations

  • Peter J. Kahrilas
    • 1
    • 5
  • Philip Miner
    • 2
  • John Johanson
    • 3
  • Lian Mao
    • 4
  • Leonard Jokubaitis
    • 4
  • Sheldon Sloan
    • 5
  1. 1.Northwestern University Feinberg School of MedicineChicago
  2. 2.Oklahoma Foundation for Digestive ResearchOklahoma City
  3. 3.Rockford Gastroenterology AssociatesRockford
  4. 4.Janssen Pharmaceutica Inc.Titusville
  5. 5.Section of GastroenterologyChicago

Personalised recommendations